Skip to content

Guidelines

TL;DR

  • No major guideline governs LUSC in isolation; recommendations sit within lung-cancer or NSCLC guidance and become histology-specific at pathology, cytotoxic-drug, haemorrhage-risk, and molecular-testing decisions.
  • The document name is not enough. Record organization, version/date, jurisdiction, stage edition, biomarker assay, drug authorization, and access date.
  • Broad agreement is stronger than apparent drug-list differences: multidisciplinary diagnosis and staging; low-dose CT for eligible high-risk asymptomatic people; curative local therapy for localized disease; perioperative systemic therapy for selected resectable higher-risk disease; chemoradiation plus consolidation immunotherapy for eligible unresectable stage III disease; and PD-L1-/driver-informed systemic therapy for stage IV disease.
  • Divergence commonly reflects approval timing, reimbursement, population eligibility, and update method rather than contradictory biology.
  • The ninth TNM edition is now the staging frame, but older guidance may map recommendations to seventh- or eighth-edition groups. Never apply a stage label across editions without checking descriptors.
  • Guidelines guide; they do not replace pathology review, multidisciplinary resectability assessment, patient preference, comorbidity, or urgent management of airway obstruction, haemoptysis, infection, and other emergencies.

How to read a guideline safely

Field Why it matters Failure mode if omitted
Issuer and jurisdiction Determines approval, resource, and service assumptions Importing an unavailable or unreimbursed regimen
Version and access date Living guidance can change several times yearly Citing an obsolete algorithm as current
Evidence-search cutoff Recommendations lag trials by different intervals Treating omission as negative evidence
TNM edition The same stage label may represent different anatomy Misapplying an old stage-based recommendation
Histology Pemetrexed and bevacizumab constraints are squamous-relevant Using an all-NSCLC list without histology filters
Biomarker definition TPS, CPS, tumour-cell, and immune-cell scores differ Applying the wrong threshold or assay
Strength and certainty “Offer,” “consider,” and consensus are not equivalent Presenting preference-sensitive care as mandatory
Population exclusions Trials often exclude ECOG ≥2, autoimmune disease, transplant, or untreated CNS disease Overstating transportability
Patient values Net benefit depends on function, toxicity, time, and goals Technically compliant but person-inappropriate care

Core sources current at this review

Scope Source Current item checked Use in LUSC Important caveat
Stage IV without driver alterations ASCO living guideline PubMed-indexed version 2026.3.1 First and subsequent systemic therapy by histology and PD-L1 The living landing page was access-blocked during this audit, so no newer web version is asserted here ([PMID 42190141](https://pubmed.ncbi.nlm.nih.gov/42190141/){target="_blank" rel="noopener"})
Stage III ASCO Full guideline, 2022 Concurrent chemoradiation, consolidation, selected surgery questions New perioperative evidence may require later updates ([PMID 34936470](https://pubmed.ncbi.nlm.nih.gov/34936470/){target="_blank" rel="noopener"})
Diagnosis and management NICE NG122 Updated 8 March 2024; reviewed 10 February 2026 Open-access pathway from diagnosis through palliative care Recommendations were developed using AJCC seventh-edition staging; linked technology appraisals update drugs (official NICE)
Molecular testing CAP/IASLC/AMP 2018 update and current resource page Tissue stewardship and testing standards Target list predates many modern approvals; use current drug guidance too (IASLC resource; [PMID 29398453](https://pubmed.ncbi.nlm.nih.gov/29398453/){target="_blank" rel="noopener"})
Lung screening USPSTF 2021 recommendation US eligibility and annual LDCT US-specific age/smoking rule; symptoms require diagnosis, not screening (official USPSTF; [PMID 33687470](https://pubmed.ncbi.nlm.nih.gov/33687470/){target="_blank" rel="noopener"})
Lung screening American Cancer Society 2023 update Annual LDCT for eligible people aged 50–80 with ≥20 pack-years Unlike USPSTF, former-smoker eligibility is not stopped solely at 15 quit-years ([PMID 37909877](https://pubmed.ncbi.nlm.nih.gov/37909877/){target="_blank" rel="noopener"})
Early-stage radiation ASTRO Evidence-based SBRT guideline Medically inoperable and selected high-risk contexts Predates modern sublobar randomized trials and perioperative immunotherapy ([PMID 28596092](https://pubmed.ncbi.nlm.nih.gov/28596092/){target="_blank" rel="noopener"})
Oligometastatic NSCLC ASTRO/ESTRO 2023 clinical-practice guideline Local therapy integration with systemic care Applies to carefully selected limited disease, not all stage IV NSCLC ([PMID 37294262](https://pubmed.ncbi.nlm.nih.gov/37294262/){target="_blank" rel="noopener"})
Brain metastases ASCO/SNO/ASTRO 2022 guideline Surgery, stereotactic radiation, whole-brain radiation, and systemic-therapy coordination Neurological instability overrides elective sequencing ([PMID 34932393](https://pubmed.ncbi.nlm.nih.gov/34932393/){target="_blank" rel="noopener"})

Screening and referral

Screening applies to an asymptomatic high-risk population. USPSTF recommends annual low-dose CT for US adults aged 50–80 with at least 20 pack-years who currently smoke or quit within 15 years ([PMID 33687470](https://pubmed.ncbi.nlm.nih.gov/33687470/){target="_blank" rel="noopener"}). The ACS 2023 update uses ages 50–80 and at least 20 pack-years but removes years-since-quitting as an exclusion ([PMID 37909877](https://pubmed.ncbi.nlm.nih.gov/37909877/){target="_blank" rel="noopener"}). Both require that a person could and would undergo diagnostic work-up and treatment.

These are not interchangeable global rules. Program capacity, background incidence, smoking patterns, health economics, and national policy matter. Any eligible program should incorporate shared decision-making, smoking-cessation support, nodule-management protocols, radiation-quality control, and tracking of false-positive downstream procedures.

Symptoms leave the screening pathway. NICE recommends a suspected-cancer referral for unexplained haemoptysis in people aged 40 or older and urgent chest radiography for specified symptom combinations, with lower symptom-count threshold in ever-smokers (official NICE suspected-cancer guidance). A normal radiograph does not close a high-suspicion case.

Diagnosis, tissue, and mediastinal staging

Guidelines converge on obtaining the safest specimen that establishes diagnosis and stage while preserving material for immunohistochemistry and molecular testing. NICE explicitly places suspected cases in a lung-cancer multidisciplinary team and recommends EBUS/EUS pathways for mediastinal assessment, with surgical staging after a negative needle procedure when suspicion remains high and nodal status would change treatment (NICE diagnosis and staging).

CAP/IASLC/AMP recommends validated molecular methods and emphasizes sample adequacy and turnaround ([PMID 29398453](https://pubmed.ncbi.nlm.nih.gov/29398453/){target="_blank" rel="noopener"}). The guideline's original EGFR/ALK focus should not be mistaken for a ceiling on contemporary broad profiling. LUSC has a lower rate of classic oncogenic drivers than adenocarcinoma but has extensive genomic complexity ([PMID 22960745](https://pubmed.ncbi.nlm.nih.gov/22960745/){target="_blank" rel="noopener"}). Clinical features such as never-smoking, young age, mixed morphology, or scant biopsy further support comprehensive testing.

PD-L1 reports should name the assay and score. Blueprint testing showed that 22C3, 28-8, and SP263 tumour-cell staining were often comparable, whereas SP142 labelled fewer tumour cells and immune-cell scoring was less concordant ([PMID 27913228](https://pubmed.ncbi.nlm.nih.gov/27913228/){target="_blank" rel="noopener"}). Guideline thresholds cannot safely migrate between unlike scoring systems.

Staging and multidisciplinary decisions

Ninth-edition TNM subdivides N2 and M1c categories and updates stage groups; the IASLC proposal provides the primary evidence base ([PMID 38447919](https://pubmed.ncbi.nlm.nih.gov/38447919/){target="_blank" rel="noopener"}). Older guidance may retain seventh- or eighth-edition labels. Store the actual T, N, and M descriptors, not only “stage III.”

Clinical state Guideline-level default Mandatory qualifications
Operable stage I Anatomic resection with nodal evaluation Segmentectomy/sublobar eligibility is limited to carefully staged small peripheral disease
Medically inoperable stage I SABR Central/ultracentral location changes fractionation and toxicity planning
Resectable higher-risk stage II–III Multimodality treatment; perioperative chemo-immunotherapy is now a standard option in eligible driver-negative disease Resectability, stage definition, biomarker exclusions, and ability to complete surgery
Completely resected stage II–III Cisplatin-based chemotherapy; selected adjuvant immunotherapy Prior neoadjuvant therapy, PD-L1, driver status, recovery, and jurisdiction
Unresectable stage III Concurrent platinum chemoradiation when fit, then consolidation immunotherapy if no progression Sequential therapy if concurrent treatment is unsafe; pneumonitis and autoimmune risk
Metastatic, driver-negative LUSC PD-1/PD-L1-based treatment with squamous-compatible chemotherapy or selected immune-only strategy PD-L1, disease tempo, performance status, contraindications, and patient goals
Oligometastatic/oligoprogressive Consider definitive local therapy to all relevant sites Limited number, technically safe treatment, controlled systemic disease, multidisciplinary selection

Localized disease

NICE offers lobectomy for fit patients and requires hilar and mediastinal nodal sampling or en-bloc resection (NICE management). Since older guidelines were drafted, JCOG0802 and CALGB 140503 demonstrated that selected peripheral tumours no larger than 2 cm can undergo protocol-defined segmentectomy or sublobar resection without sacrificing the principal survival endpoint ([PMID 35461558](https://pubmed.ncbi.nlm.nih.gov/35461558/){target="_blank" rel="noopener"}; [PMID 36780674](https://pubmed.ncbi.nlm.nih.gov/36780674/){target="_blank" rel="noopener"}). The selection criteria and intraoperative nodal confirmation are part of the evidence.

Physiological operability uses predicted postoperative lung function, exercise capacity, and cardiac/comorbidity assessment rather than age alone. ERS/ESTS guidance established a structured radical-treatment fitness pathway ([PMID 19477657](https://pubmed.ncbi.nlm.nih.gov/19477657/){target="_blank" rel="noopener"}). SABR guidance supports curative treatment in medically inoperable early NSCLC ([PMID 28596092](https://pubmed.ncbi.nlm.nih.gov/28596092/){target="_blank" rel="noopener"}).

Adjuvant cisplatin-based chemotherapy has an absolute five-year survival gain of about 5.4 percentage points across resected NSCLC, with benefit concentrated in stage II–III ([PMID 18506026](https://pubmed.ncbi.nlm.nih.gov/18506026/){target="_blank" rel="noopener"}). This is the base on which newer perioperative recommendations sit.

Perioperative immunotherapy update logic

Guidelines now incorporate one of two broad patterns:

  1. neoadjuvant chemotherapy plus checkpoint inhibitor followed by surgery, as supported by CheckMate 816 ([PMID 35403841](https://pubmed.ncbi.nlm.nih.gov/35403841/){target="_blank" rel="noopener"}); or
  2. neoadjuvant chemo-immunotherapy followed by surgery and adjuvant checkpoint inhibitor, as supported by KEYNOTE-671, AEGEAN, and CheckMate 77T ([PMID 37272513](https://pubmed.ncbi.nlm.nih.gov/37272513/){target="_blank" rel="noopener"}; [PMID 37870974](https://pubmed.ncbi.nlm.nih.gov/37870974/){target="_blank" rel="noopener"}; [PMID 38749033](https://pubmed.ncbi.nlm.nih.gov/38749033/){target="_blank" rel="noopener"}).

No randomized comparison isolates the value of the postoperative component; indirect cross-trial comparisons remain confounded by regimen, population, and staging differences. EGFR/ALK exclusions, tumour-size thresholds, stage editions, and approvals vary. Adjuvant-only atezolizumab and pembrolizumab evidence also differs by PD-L1 subgroup and trial design ([PMID 34555333](https://pubmed.ncbi.nlm.nih.gov/34555333/){target="_blank" rel="noopener"}; [PMID 36108662](https://pubmed.ncbi.nlm.nih.gov/36108662/){target="_blank" rel="noopener"}).

Unresectable stage III

ASCO recommends concurrent chemoradiation for fit patients and supports consolidation durvalumab after definitive chemoradiation without progression ([PMID 34936470](https://pubmed.ncbi.nlm.nih.gov/34936470/){target="_blank" rel="noopener"}). PACIFIC established PFS and OS benefit ([PMID 28885881](https://pubmed.ncbi.nlm.nih.gov/28885881/){target="_blank" rel="noopener"}); five-year OS was 42.9% with durvalumab versus 33.4% with placebo ([PMID 35108059](https://pubmed.ncbi.nlm.nih.gov/35108059/){target="_blank" rel="noopener"}).

“Unresectable” should be a prospective multidisciplinary judgment, not shorthand inferred from stage alone. A guideline-concordant pathway also includes radiation dose/volume quality, pulmonary-function assessment, nutrition, cessation support, and early recognition of pneumonitis.

Metastatic LUSC

The PubMed-indexed ASCO living-guideline publication is version 2026.3.1 ([PMID 42190141](https://pubmed.ncbi.nlm.nih.gov/42190141/){target="_blank" rel="noopener"}). The web landing page can advance between publications but returned an access block during this audit, so the version must be rechecked at treatment use. For driver-negative squamous disease, major evidence-supported first-line families are:

Pemetrexed is not a squamous regimen. Bevacizumab is generally avoided because squamous histology, central cavitation, and haemoptysis heighten catastrophic pulmonary-bleeding concern. Subsequent therapy depends on prior exposure; older immunotherapy-versus-docetaxel trials apply most directly to checkpoint-naïve patients, while modern post-chemo-immunotherapy evidence remains sparse.

CNS, oligometastatic, and supportive-care guidance

The ASCO/SNO/ASTRO brain-metastasis guideline coordinates surgery, stereotactic radiosurgery, whole-brain radiation, and systemic therapy ([PMID 34932393](https://pubmed.ncbi.nlm.nih.gov/34932393/){target="_blank" rel="noopener"}). Symptomatic brain metastases generally require local therapy and neurological stabilization; a systemic agent's intracranial activity does not justify delay in an unstable patient.

ASTRO/ESTRO conditionally supports integrating definitive local therapy for carefully selected oligometastatic NSCLC when all sites can be treated safely ([PMID 37294262](https://pubmed.ncbi.nlm.nih.gov/37294262/){target="_blank" rel="noopener"}). The evidence is not a mandate to irradiate widespread disease.

NICE includes early monitoring and access to debulking, stenting, or radiotherapy for impending endobronchial obstruction (NICE palliative interventions). Randomized evidence supports early palliative care alongside oncology: better quality of life and mood, less aggressive end-of-life care, and longer median survival in metastatic NSCLC ([PMID 20818875](https://pubmed.ncbi.nlm.nih.gov/20818875/){target="_blank" rel="noopener"}).

Where guidelines legitimately differ

Apparent conflict Likely explanation Resolution
Different screening eligibility Different health-system modeling and quit-year policy Apply the governing national program and document shared decision
Different perioperative drug lists Approval/reimbursement date and update cadence Check living guideline plus local authorization on treatment date
PD-L1 threshold mismatch Different regimen, assay, disease setting, or regulator Return to the pivotal trial and companion assay
Surgery vs radiation wording Operability, lesion location, institutional expertise Thoracic multidisciplinary review with patient preference
Broad vs selective molecular testing Older evidence cutoff and resource assumptions Use current comprehensive-testing standards and local access
Treatment “recommended” vs “option” Evidence certainty, cost-effectiveness, and wording convention Read strength, certainty, and qualifying remarks

Audit checklist

  • [ ] Histology confirmed and mimics excluded.
  • [ ] TNM descriptors and edition documented.
  • [ ] Mediastinal staging adequate for the proposed intent.
  • [ ] Molecular and PD-L1 assays named, with specimen date/site.
  • [ ] Guideline organization, version, jurisdiction, and access date recorded.
  • [ ] Recommendation strength and evidence certainty preserved.
  • [ ] Approval and reimbursement checked locally.
  • [ ] Trial population compared with the patient's fitness and comorbidity.
  • [ ] Multidisciplinary decision and patient preference documented.
  • [ ] Safety-net plan covers bleeding, obstruction, infection, thrombosis, CNS symptoms, and treatment toxicity.

Open questions

  1. How can living guidelines expose recommendation changes in machine-readable form without losing qualifying text?
  2. When should ninth-edition TNM remapping trigger formal re-review of older treatment recommendations?
  3. Can guideline panels distinguish LUSC subgroup evidence from all-NSCLC inference more consistently?
  4. How should resource-limited settings prioritize PD-L1, broad sequencing, and perioperative therapy?
  5. Which implementation measures—time to tissue, molecular completion, MDT review, or treatment delivery—most improve outcomes?

References

  1. Bazhenova L, Ismaila N, Durm G, Freeman-Daily J, Horinouchi H, MacVicar GR, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1. J Clin Oncol. 2026;44(18):e101-e112. PMID 42190141
  2. Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2022;40(12):1356-1384. PMID 34936470
  3. NICE. Lung cancer: diagnosis and management, NG122. Official source
  4. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018;20(2):129-159. PMID 29398453
  5. US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962-970. PMID 33687470
  6. Wolf AMD, Oeffinger KC, Shih TY, Walter LC, Church TR, Fontham ETH, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2024;74(1):50-81. PMID 37909877
  7. Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7(5):295-301. PMID 28596092
  8. Iyengar P, All S, Berry MF, Boike TP, Bradfield L, Dingemans AC, et al. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Pract Radiat Oncol. 2023;13(5):393-412. PMID 37294262
  9. Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022;40(5):492-516. PMID 34932393
  10. Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2024;19(7):1007-1027. PMID 38447919
  11. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519-25. PMID 22960745
  12. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12(2):208-222. PMID 27913228
  13. Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607-1617. PMID 35461558
  14. Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023;388(6):489-498. PMID 36780674
  15. Brunelli A, Charloux A, Bolliger CT, Rocco G, Sculier JP, Varela G, et al. The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. Eur J Cardiothorac Surg. 2009;36(1):181-4. PMID 19477657
  16. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-9. PMID 18506026
  17. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985. PMID 35403841
  18. Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(6):491-503. PMID 37272513
  19. Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. N Engl J Med. 2023;389(18):1672-1684. PMID 37870974
  20. Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024;390(19):1756-1769. PMID 38749033
  21. Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344-1357. PMID 34555333
  22. O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274-1286. PMID 36108662
  23. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919-1929. PMID 28885881
  24. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301-1311. PMID 35108059
  25. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040-2051. PMID 30280635
  26. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-42. PMID 20818875